SK 596. Cancer Diagnosis and Prognosis by Determining Levels of MDM2 and p53 and Antibodies Against MDM2

Summary of Invention

The invention provides a method for diagnosing cancer by determining the expression levels or the degrees of gene amplification of p53 and MDM2, whereby an elevated level of either gene or either protein would indicate a cancer diagnosis. Furthermore, the invention provides a method of predicting the progress of cancer, whereby elevated levels of either gene or either protein would indicate a poor prognosis.

Also provided are five monoclonal antibodies against the human MDM2 protein.

Advantages

Monoclonal MDM2 antibodies useful for histochemistry.

Areas of Application

Method to aid in the diagnosis and prognosis of several cancers.

Lead Inventor

Dr. Arnold J. Levine

Patent Information

• US patent 5,843,684.
• Patent prosecution ongoing in several major countries.
• Available for a nonexclusive license.

Contact Information

Jeffrey Horenstein, PhD
Tel: 212-639-6181; Fax: 212-717-3439
E-mail: horenstj@mskcc.org